X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 21, 2024
Details:
The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: LENZ Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2024
Details:
Under the agreement, Kamau will focus on the clinical development of lead program Nula-Cel (nulabeglogene autogedtemcel), which is being evaluated in Phase I/II clinical trial studies for the treatment of sickle cell disease.
Lead Product(s): Nulabeglogene Autogedtemcel
Therapeutic Area: Hematology Product Name: Nula-Cel
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kamau Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2023
Details:
The combined will focus on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LENZ Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 15, 2023
Details:
The net proceeds will be used on the advancement of LENZ’s lead programs, LNZ100 and LNZ101, which are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively, for the treatment of presbyopia.
Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate
Therapeutic Area: Ophthalmology Product Name: LNZ101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $53.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 15, 2023
Details:
GPH101 (nula-cel), is an investigational next-generation gene editing autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).
Lead Product(s): Nulabeglogene Autogedtemcel
Therapeutic Area: Genetic Disease Product Name: GPH101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Nula-cel, formerly known as GPH101, is an investigational next-generation gene-editing autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD).
Lead Product(s): Nulabeglogene Autogedtemcel
Therapeutic Area: Genetic Disease Product Name: GPH101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
GPH102 is designed to replace the mutated beta-globin gene with a functional gene and restore adult hemoglobin (HbA) expression to levels similar to individuals who do not have the disease.
Lead Product(s): GPH102
Therapeutic Area: Genetic Disease Product Name: GPH102
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
First patient expected to be treated by GPH101 in first half of 2022, GPH101 an investigational next-generation gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.
Lead Product(s): GPH101
Therapeutic Area: Genetic Disease Product Name: GPH101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2021
Details:
The preclinical data support CEDAR clinical trial, a Phase 1/2 study evaluating the safety, pharmacodynamics, engraftment success, gene correction rates and total hemoglobin, as well as other clinical and exploratory endpoints of GPH101 in patients with severe SCD.
Lead Product(s): GPH101
Therapeutic Area: Genetic Disease Product Name: GPH101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
